Opinion|Videos|November 13, 2026

Platinum-Resistant Ovarian Cancer: The Problem and the Current Standard of Care

EPISODE 1 META (150–160 CHAR) Drs. Miller and Vue frame platinum-resistant ovarian cancer, define the 6-month threshold, and review the bevacizumab, mirvetuximab, and T-DXd backbone of current care.

Vue:Welcome to this Between the Lines with CancerNetwork. My goal in the next few minutes is to take a piece of new evidence and make it clear and useful — the kind of explanation that a busy colleague or an informed patient could easily follow. Let’s get started. My name is Nujsaubnusi Vue, and I’m a gynecologic oncologist in Pittsburgh, Pennsylvania.

Miller:And my name is Eirwen Miller. I’m also a gynecologic oncologist at Allegheny Health Network in Pittsburgh, Pennsylvania. Today we’re going to talk about platinum-resistant ovarian cancer. Ovarian cancer is a rare gynecologic malignancy that is often diagnosed at advanced stage, and once it becomes platinum resistant, treatment options have historically been limited.

Vue:Platinum resistance is defined as ovarian cancer that recurs within 6 months of completing platinum-based therapy. It is one of the most challenging diseases we treat, because the options in this setting have been so limited. So, Dr. Miller, walk me through the current standard-of-care treatment options for platinum-resistant ovarian cancer.

Miller:That’s a great question. In the past 6 to 12 months we’ve had some truly practice-moving data emerge in this space. Historically, we’ve treated patients with a chemotherapy backbone plus bevacizumab, based on the AURELIA trial, which demonstrated a survival benefit when bevacizumab was added to single-agent chemotherapy. We also have targeted options — mirvetuximab soravtansine for patients whose tumors overexpress folate receptor alpha, and trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing disease. Until recently, those options formed the foundation of my treatment algorithm in platinum-resistant disease. But in the last several months, data from the KEYNOTE-B96 trial and the ROSELLA trial have shown meaningful treatment benefit, and that has really reset the landscape. Is there a particular choice between KEYNOTE-B96 and ROSELLA that you find interesting?


Related to this article